Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bruker Cellular Analysis, Inc.CELL · Entity 109250 | Chief Financial Officer | October 02, 2023 | October 03, 2023 |
| Pulmonx CorpLUNG · Entity 2359 | Chief Financial Officer & PAO | September 02, 2025 | September 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bruker Cellular Analysis, Inc.
Report date October 02, 2023 · Filed October 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-10-02 · Exercise / conversion · Disposed 775,517 · Balance 65,013 F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2: Pursuant to the Merger, the Reporting Person disposed of each RSU held by him in exchange for the Merger Consideration. Row 2 · 2023-10-02 · Disposition to issuer · Disposed 65,013 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F4: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration").
F2: Pursuant to the Merger, the Reporting Person disposed of each RSU held by him in exchange for the Merger Consideration.
F3: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration.
F4: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration.
Pulmonx Corp
Report date September 02, 2025 · Filed September 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,154 |
Reported balance
After 2025-09-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-09-02 · Sale · Disposed 4,271 · Balance 212,154 F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on May 6, 2024. F2: Includes 2,500 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on August 15, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 208,489 |
Reported balance
After 2025-09-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-09-02 · Sale · Disposed 3,665 · Balance 208,489 F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on May 6, 2024.
F2: Includes 2,500 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on August 15, 2025.
F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2025 Filed Sep 3, 2025 21:12 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 3,665 | $1.60 | $5,864.00 |
DisclosureSEC source: 0001415889-25-023573 · form4-09032025_090938.xml · nonDerivative · entry 2 Joshi Mehul · CIK 0001939602 · Chief Financial Officer & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,489 F3 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:12 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,271 | $1.60 | $6,833.60 |
DisclosureSEC source: 0001415889-25-023573 · form4-09032025_090938.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,154 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on May 6, 2024. F2 · balance_after: Includes 2,500 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on August 15, 2025. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 22:10 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 3,721 | $3.13 | $11,646.73 |
DisclosureSEC source: 0001415889-25-015646 · form4-06042025_100628.xml · nonDerivative · entry 2 Joshi Mehul · CIK 0001939602 · Chief Financial Officer & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,925 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 22:10 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,340 | $3.13 | $13,584.20 |
DisclosureSEC source: 0001415889-25-015646 · form4-06042025_100628.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,646 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on May 6, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 23:12 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantCommon Stock | 108,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007043 · form4-03052025_110357.xml · nonDerivative · entry 2 Joshi Mehul · CIK 0001939602 · Chief Financial Officer & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,986 F3 · shares: Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 3, 2025. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 23:12 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 14,384 | $7.12 | $102,414.08 |
DisclosureSEC source: 0001415889-25-007043 · form4-03052025_110357.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,986 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on May 6, 2024. F2 · balance_after: Includes 2,500 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on February 21, 2025. Read SEC document |
| May 06, 2024 Filed May 7, 2024 21:44 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantEmployee Stock Option (right to buy) · Derivative | 241,409 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001415889-24-012499 · form4-05072024_090522.xml · derivative · entry 2 Joshi Mehul · CIK 0001939602 · Chief Financial Officer & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,409 Underlying: Common Stock · 241,409 shares Expires 2034-05-05 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on March 3, 2025, and the remainder vests in equal monthly installments over the subsequent three-year period. Read SEC document |
| May 06, 2024 Filed May 7, 2024 21:44 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantCommon Stock | 125,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012499 · form4-05072024_090522.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,870 F1 · shares: Represents grant of Restricted Stock Units award payable solely in common stock of the Issuer that vest in accordance with the following schedule: 25% vests on March 3, 2025, and the remainder of the award vests in equal quarterly installments over the subsequent three-year period. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 15:24 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Disposition to issuerCommon Stock | 65,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019733 · doc4.xml · nonDerivative · entry 2 Joshi Mehul · CIK 0001939602 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F4 · price: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 15:24 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Exercise / conversionCommon Stock | 775,517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019733 · doc4.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F1 · price: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2 · price: Pursuant to the Merger, the Reporting Person disposed of each RSU held by him in exchange for the Merger Consideration. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 16:15 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Tax withholdingCommon Stock | 26,412 | $0.55 | $14,526.60 |
DisclosureSEC source: 0001104659-23-085332 · tm2322343-1_4seq1.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 840,530 F1 · shares: Reflects shares sold by the Reporting Person pursuant to a pre-determined election in order to cover tax withholding obligations incurred in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes 775,517 RSUs. Read SEC document |
| May 29, 2023 Filed Jun 1, 2023 16:16 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | GrantCommon Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-067040 · tm2317396d8_4.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 866,942 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest with respect to 25% of the shares on May 29, 2024, and will vest with respect to the remainder of the shares in equal quarterly installments thereafter until fully vested on May 29, 2027, subject to continued service through each applicable vesting date. F2 · balance_after: Includes 847,356 RSUs. Read SEC document |
| March 07, 2023 Filed Mar 7, 2023 20:22 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | Tax withholdingCommon Stock | 14,818 | $1.65 | $24,449.70 |
DisclosureSEC source: 0001104659-23-029746 · tm237589-3_4seq1.xml · nonDerivative · entry 2 Joshi Mehul · CIK 0001939602 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,942 F2 · shares: Reflects shares sold by the Reporting Person pursuant to a pre-determined election in order to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F3 · balance_after: Includes 497,356 restricted stock units and 2,000 shares purchased by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan at a price equal to 85% of the closing price of Issuer's Common Stock on March 6, 2023. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 20:22 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 242,404 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-029746 · tm237589-3_4seq1.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,760 F1 · shares: Represents awards of (i) 32,404 restricted stock units in lieu of cash bonus earned for 2022, which vested in full on March 3, 2023 and were settled in shares of the Issuer's common stock upon vesting, and (ii) 210,000 restricted stock units, of which twenty-five percent will vest on February 20, 2024, with the remainder vesting in twelve equal quarterly installments on the 20th day of the second month of each quarter of the calendar year. The restricted stock units were granted pursuant to the Issuer's 2020 Incentive Award Plan. Read SEC document |
| July 25, 2022 Filed Jul 26, 2022 21:50 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 451,208 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001567619-22-014509 · doc1.xml · derivative · entry 2 Joshi Mehul · CIK 0001939602 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,208 Underlying: Common Stock · 451,208 shares Expires 2032-07-24 F3 · derivative.exercise_date: The stock options will vest with respect to 25% of the shares on July 25, 2023, and will vest with respect to the remainder of the shares in equal monthly installments thereafter until fully vested on July 25, 2026. Read SEC document |
| July 25, 2022 Filed Jul 26, 2022 21:50 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 287,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014509 · doc1.xml · nonDerivative · entry 1 Joshi Mehul · CIK 0001939602 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,356 F1 · shares: Represents an award of restricted stock units which will vest with respect to 25% of the shares on July 25, 2023, and will vest with respect to the remainder of the shares in equal monthly installments thereafter until fully vested on July 25, 2026. The restricted stock units will be settled in shares of the Issuer's common stock upon vesting. F2 · balance_after: Includes 287,356 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.